Product: Anti-human Caspase-3 (CPP2), Polyclonal
Cat. No: PC-055 (250 μg)
Background:
Caspase-3 along with caspase 7 and 6 form the
group of effector caspases that are responsible
for the cleavage of multiple substrates including
the cytokeratins, PARP, alpha fodrin, NuMA and
others. Caspase-7 occurs in three varient forms.
Caspase-3-like activities are required for Fasmediated
apoptosis. However, the role of
caspase-1 and caspase-3 in mediating Fasinduced
cell death is not clear. Although wildtype,
caspase-1(-/-), and caspase-3(-/-)
hepatocytes were killed at a similar rate when
cocultured with FasL expressing NIH 3T3 cells,
caspase-3(-/-) hepatocytes displayed drastically
different morphological changes as well as
significantly delayed DNA fragmentation. For
both wild-type and caspase-1(-/-) apoptotic
hepatocytes, typical apoptotic features such as
cytoplasmic blebbing and nuclear fragmentation
are seen within 6 hr, but neither event was
observed for caspase-3(-/-) hepatocytes. In
thymocytes apoptotic caspase-3(-/-) thymocytes
exhibit similar "abnormal" morphological
changes and delayed DNA fragmentation
observed in hepatocytes. Cleavage of various
caspase substrates implicates apoptotic events,
including gelsolin, fodrin, laminB, and
DFF45/ICAD are delayed or absent. The altered
cleavage of these key substrates is likely
responsible for the aberrant apoptosis observed
in both hepatocytes and thymocytes deficient in
caspase-3.
Specificity:
Recognizes pro-caspase-3.
Species Reactivity:
Human, other species not tested.
Ig Isotype:
Rabbit IgG
Immunogen:
Full length recombinant caspase-3.
Format:
250 μg purified IgG at 1 mg/ml in PBS with
0.05% sodium azide
Storage and Stability:
Antibodies should be stored at -20°C. Aliquot to
avoid freeze/thaw cycles.
Applications and Suggested Dilutions:

Western blot: Use at 2-10 μg/ml
The optimal dilution for a specific application
should be determined by the researcher.
Limitations:
For in vitro research use only. Not for use in
diagnostics or in humans.
Warranty:
No warranties, expressed or implied, are made
regarding the use of this product. KAMIYA
BIOMEDICAL COMPANY is not liable for any
damage, personal injury, or economic loss
caused by this product.